Literature DB >> 27748022

Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature.

Job Verdonschot1, Mark Hazebroek1, Jort Merken1, Yannick Debing1, Robert Dennert1, Hans-Peter Brunner-La Rocca1, Stephane Heymans1.   

Abstract

Over the last decade, parvovirus B19 (B19V) has frequently been linked to the pathogenesis of myocarditis (MC) and its progression towards dilated cardiomyopathy (DCM). The exact role of the presence of B19V and its load remains controversial, as this virus is also found in the heart of healthy subjects. Moreover, the prognostic relevance of B19V prevalence in endomyocardial biopsies still remains unclear. As a result, it is unclear whether the presence of B19V should be treated. This review provides an overview of recent literature investigating the presence of B19V and its pathophysiological relevance in MC and DCM, as well as in normal hearts. In brief, no difference in B19V prevalence is observed between MC/DCM and healthy control hearts. Therefore, the question remains open whether and how cardiac B19V may be of pathogenetic importance. Findings suggest that B19V is aetiologically relevant either in the presence of other cardiotropic viruses, or when B19V load is high and/or actively replicating, which both may maintain myocardial (low-grade) inflammation. Therefore, future studies should focus on the prognostic relevance of the viral load, replicative status and virus co-infections. In addition, the immunogenetic background of MC/DCM patients that makes them susceptible to develop heart failure upon presence of B19V should be more thoroughly investigated.
© 2016 The Authors. European Journal of Heart Failure © 2016 European Society of Cardiology.

Entities:  

Keywords:  Dilated cardiomyopathy; Endomyocardial biopsy; Myocarditis; Parvovirus B19; Prognosis; Viral load

Mesh:

Year:  2016        PMID: 27748022     DOI: 10.1002/ejhf.665

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  41 in total

Review 1.  Evolutionary aspects of Parvovirus B-19V associated diseases and their pathogenesis patterns with an emphasis on vaccine development.

Authors:  Piyanki Das; Koustav Chatterjee; Nabanita Roy Chattopadhyay; Tathagata Choudhuri
Journal:  Virusdisease       Date:  2019-03-26

2.  [Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with Nivolumab].

Authors:  R Sauer; P Kiewe; M Desole; M Schuler; F Theissig; A Roth; T Mairinger
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

3.  Molecular Mechanisms behind Persistent Presence of Parvovirus B19 in Human Dilated Myocardium.

Authors:  Daiva Bironaitė; Ieva Kažukauskienė; Julius Bogomolovas; Dainius Daunoravičius; Artūras Jakubauskas; Dalius Vitkus; Edvardas Žurauskas; Kęstutis Ručinskas; Siegfried Labeit; Virginija Grabauskiene
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Parvovirus B19 myocarditis in children: a diagnostic and therapeutic approach.

Authors:  Roger Esmel-Vilomara; Paola Dolader; Jaume Izquierdo-Blasco; Joan Balcells; Moisés Sorlí; Fuensanta Escudero; Elena Vera; Ferran Gran
Journal:  Eur J Pediatr       Date:  2022-02-09       Impact factor: 3.183

Review 5.  The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Authors:  Julian G Westphal; Angelos G Rigopoulos; Constantinos Bakogiannis; Sarah E Ludwig; Sophie Mavrogeni; Boris Bigalke; Torsten Doenst; Matthias Pauschinger; Carsten Tschöpe; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 6.  Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment.

Authors:  Enrico Ammirati; Giacomo Veronese; Manlio Cipriani; Francesco Moroni; Andrea Garascia; Michela Brambatti; Eric D Adler; Maria Frigerio
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

7.  The potential role of plasma miR-155 and miR-206 as circulatory biomarkers in inflammatory cardiomyopathy.

Authors:  Danilo Obradovic; Karl-Philipp Rommel; Stephan Blazek; Karin Klingel; Matthias Gutberlet; Christian Lücke; Petra Büttner; Holger Thiele; Volker Adams; Philipp Lurz; Fabian Emrich; Christian Besler
Journal:  ESC Heart Fail       Date:  2021-04-08

8.  Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients.

Authors:  Heinz-Peter Schultheiss; Thomas Bock; Heiko Pietsch; Ganna Aleshcheva; Christian Baumeier; Friedrich Fruhwald; Felicitas Escher
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

Review 9.  [Inflammatory cardiomyopathy and myocarditis].

Authors:  B Maisch; A D Ristic; S Pankuweit
Journal:  Herz       Date:  2017-06       Impact factor: 1.740

Review 10.  Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy.

Authors:  Sophie Van Linthout; Carsten Tschöpe
Journal:  Curr Opin Cardiol       Date:  2018-05       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.